Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes.
暂无分享,去创建一个
M. Baccarani | M. Vignetti | F. Mandelli | K. Cocks | F. Efficace | M. Breccia | C. Meyers | M. Sprangers | M. Sprangers